Mercy Medical Center | GI Research

Research site
301 Street Paul Place, POB 718, Baltimore, Maryland, United States of America
Site insights

Top conditions

Breast Cancer (43 trials)

Hepatitis (23 trials)

Hepatitis C (20 trials)

Non-alcoholic Fatty Liver Disease (20 trials)

Fatty Liver (19 trials)

Top treatments

Obeticholic Acid

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site


31 of 158
Status: Active
Trial type: Interventional
Funder type: Industry

A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)

This study will determine the effect of oral 80 mg resmetirom administered once daily on participants with well-compensated non-alcoholic steatohepat...

Cirrhosis, Liver
Drug: Resmetirom
Drug: Placebo

This study is researching an investigational drug called ALN-HSD (called "study drug"). This study is focused on participants who are known to have n...

Non-alcoholic Steatohepatitis (NASH)
Metabolic Dysfunction Associated Steatohepatitis (MASH)
Drug: Placebo

The purpose of this study is to assess the efficacy and safety of tiragolumab, an anti-TIGIT monoclonal antibody, when administered in combination wi...

Carcinoma, Hepatocellular
Other: Placebo
Drug: Tiragolumab
Locations recently updated

This is a Phase III, two-arm, randomized, double-blind placebo-controlled study in participants with HER2-positive primary breast cancer who have rec...

Breast Cancer
Drug: Trastuzumab Emtansine
Drug: Placebo

This Phase III, randomized, double-blind, placebo-controlled, multicenter study will evaluate the efficacy and safety of giredestrant combined with p...

Active, not recruiting
Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
Drug: Letrozole
Drug: Giredestrant-matched Placebo

This Phase III, randomized, open-label, multicenter study will evaluate the efficacy and safety of giredestrant plus everolimus compared with the phy...

Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
Drug: Dexamethasone Mouth Rinse
Drug: LHRH Agonist

This study will evaluate the efficacy and safety of adjuvant therapy with atezolizumab plus bevacizumab compared with active surveillance in particip...

Active, not recruiting
Carcinoma, Hepatocellular
Drug: Bevacizumab
Drug: Atezolizumab

The purpose of this study is to evaluate the safety and effectiveness of JNJ-77242113 compared with placebo in participants with moderately to severe...

Colitis, Ulcerative
Drug: JNJ-77242113
Drug: Placebo

This is a multi-center, double-blind, randomized, phase III study to investigate the efficacy and safety of Nofazinlimab (CS1003) in combination with...

Active, not recruiting
Hepatocellular Carcinoma
Drug: Nofazinlimab (CS1003) Placebo+Lenvatinib
Drug: Nofazinlimab (CS1003)+Lenvatinib

This randomized, double-blind, placebo-controlled, two-arm study will assess the safety and efficacy of pertuzumab in addition to chemotherapy plus t...

Active, not recruiting
Breast Cancer
Drug: 5-Fluorouracil
Drug: Trastuzumab

The purpose of this study is to assess the efficacy and safety of a novel immunotherapy candidate, tobemstomig, in combination with nab-paclitaxel, f...

Breast Cancer
Drug: Pembrolizumab
Drug: Tobemstomig

Patients with HER2-positive primary breast cancer (BC) who do not achieve complete response after appropriate neoadjuvant therapy are at higher risk...

Active, not recruiting
HER2-Positive Primary Breast Cancer
Residual Invasive Breast Cancer
Drug: DS-8201a
Drug: T-DM1

This study will evaluate the effects of elafibranor (the study drug) in participants with Primary Sclerosing Cholangitis (PSC). PSC is a rare disease...

Primary Sclerosing Cholangitis
Drug: Elafibranor 80 mg
Drug: Placebo Matched to Elafibranor 80 mg

A phase III multi-center, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as adjuvant treatment in...

Active, not recruiting
Early Breast Cancer
Other: Endocrine Therapy
Drug: Ribociclib

The Effect of Hepatic Impairment on The Pharmacokinetics of Seladelpar: An Open-Label Study Following Oral Dosing of Seladelpar to Subjects with Prim...

Hepatic Impairment
Compensated Cirrhosis
Drug: Seladelpar 10 mg or less
Drug: Seladelpar 10 mg

The purpose of this trial is to assess dose related safety, efficacy, and pharmacokinetics (PK) of INT-787 in participants with severe alcohol-associ...

Alcohol Associated Hepatitis
Drug: Placebo
Drug: INT-787

A phase 2b, multicenter, randomized, double-blind, placebo-controlled study of HTD1801 in adult subjects with non-alcoholic steatohepatitis and liver...

Active, not recruiting
Nonalcoholic Steatohepatitis (NASH)
Type 2 Diabetes
Drug: Placebo
Drug: HTD1801

To Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects with Primary Biliary Cholangitis (PBC) and an Inco...

Primary Biliary Cholangitis
Drug: Seladelpar 10 mg
Drug: Placebo

This phase IV trial studies the side effects of intraoperative radiation therapy and how well it works in treating patients with breast cancer underg...

Stage IIA Breast Cancer
Stage IA Breast Cancer
Other: Laboratory Biomarker Analysis
Radiation: Intraoperative Radiation Therapy

RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by lowering the amount of es...

Active, not recruiting
Breast Cancer
Drug: Letrozole
Other: Placebo

Trial sponsors

Gilead Sciences logo

Gilead Sciences (14 trials)

Clinical trials

Find clinical trialsTrials by location


© Copyright 2024 Veeva Systems